H. ODAKA

Date

Signature

ORIGINALLY FILED

UTILITY PATENT APPLICATION

First Inventor harmaceutical Composition For The Treatment of Diabetes TRANSMITTAL EL 792689035 US (Only for new nonprovisional applications under 37 CFR 1.53(b)) Express Mail Label No. Assistant Commissioner for Patents APPLICATION ELEMENTS ADDRESS TO: Box Patent Application See MPEP chapter 600 concerning utility patent application contents. Washington, DC 20231 Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or 1. X nit an original and a duplicate for fee processing. Computer Program (Appendix) Applicant claims small entity status. 8. Nucleotide and/or Amino Acid Sequence Submission See 37 CFR 1.27. (if applicable, all necessary) (preferred arrangement set forth below) 3. X Computer Readable Form (CRF) - Descriptive title of the invention Specification Sequence Listing on. Cross Reference to Related Applications i CD-ROM or CD-R (2 copies), or - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, paper or a computer program listing appendix - Background of the Invention Statements verifying identity of above copies Brief Summary of the InventionBnef Description of the Drawings (if filed) ACCOMPANYING APPLICATION PARTS - Detailed Description Assignment Papers (cover sheet & document(s)) - Claim(s) 37 CFR 3 73(b) Statement Power of - Abstract of the Disclosure 10. (when there is an assignee) Attorney English Translation Document (if applicable) Drawing(s) (35 U.S.C. 113) [Total Sheets Copies of IDS Information Disclosure 12. X 5. Oath or Declaration [Total Pages Citations Statement (IDS)/PTO-1449 Newly executed (original or copy) Copy from a prior application (37 CFR 1.63 (d)) Preliminary Amendment 13 Return Receipt Postcard (MPEP 503) X 14. X b. (for continuation/divisional with Box 18 completed) (Should be specifically itemized) **DELETION OF INVENTOR(S)** Certified Copy of Priority Document(s) (if foreign priority is claimed) 15 Signed statement attached deleting inventor(s) Nonpublication Request under 35 U.S.C. 122 named in the prior application, see 37 CFR 16. 1 63(d)(2) and 1 33(b) (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. Application Data Sheet. See 37 CFR 1.76 Other: 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: 09 , 380.059 Continuation X Continuation-in-part (CIP) of prior application No Examiner R. Cook 1614 Group Art Unit For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS Customer Number or Bar Code Label Name PATERT TRADEWARK OFFICE Address City State Zip Code Country Telephone Fax Mark Chae, Phe, JD Name (Print/Type) 37,293 Registration No. (Attorney/Agent)

Burden Hour Statement This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231

PTO/SB/17 (11-00) Approved for use through 10/31/2002 OMB 0651-0032

EEE TO ANOMITTAL	Complete if Known
Under the Paperwork Reduction Act of 1995, no persons are required to u	espond to a collection of information unless it displays a valid OMB control number
	U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

(\$) 740.00

espond to a collection of into	ormation unless it displays a valid OMB control number
Co	omplete if Known
Application Number	tba
Filing Date	tba
First Named Inventor	H. ODAKA
Examiner Name	tba
Group Art Unit	tba
Attorney Docket No.	2530 US1P

METHOD OF PAYMENT	FEE CALCULATION (continued)					
1. The Commissioner is hereby authorized to charge indicated fees and credit any overnayments to	3. ADDITIONAL FEES					
Deposit	Large Small					
Account Number 500799	Entity Entity Fee Fee Fee Fee Fee Description	Fee Paid				
Deposit Talendo Charainat Indua 144	Code (\$) Code (\$)					
Account Name Takeda Chemical Indus. Ltd	105 130 205 65 Surcharge - late filing fee or oath					
Charge Any Additional Fee Required Under 37 CFR 1 16 and 1 17	127 50 227 25 Surcharge - late provisional filing fee or cover sheet					
Applicant claims small entity status See 37 CFR 1 27	139 130 139 130 Non-English specification					
2. Payment Enclosed:	147 2,520 147 2,520 For filing a request for ex parte reexamination					
Check Credit card Money Other	112 920* 112 920* Requesting publication of SIR prior to Examiner action					
FEE CALCULATION	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action					
1. BASIC FILING FEE	115 110 215 55 Extension for reply within first month					
Large Entity Small Entity	116 390 216 195 Extension for reply within second month					
Fee Fee Fee Fee Description Code (\$) Code (\$) Fee Paid	117 890 217 445 Extension for reply within third month					
104 740 004 055 1944 5	118 1,390 218 695 Extension for reply within fourth month					
101 710 201 355 Utility filling fee 740	128 1,890 228 945 Extension for reply within fifth month					
107 490 207 245 Plant filing fee	119 310 219 155 Notice of Appeal					
108 710 208 355 Reissue filing fee	120 310 220 155 Filing a brief in support of an appeal					
114 150 214 75 Provisional filing fee	121 270 221 135 Request for oral hearing					
	138 1,510 138 1,510 Petition to institute a public use proceeding					
SUBTOTAL (1) (\$)	140 110 240 55 Petition to revive - unavoidable					
2. EXTRA CLAIM FEES Fee from	141 1,240 241 620 Petition to revive - unintentional					
Extra Claims below Fee Paid	142 1,240 242 620 Utility issue fee (or reissue)					
Total Claims	143 440 243 220 Design issue fee					
Independent	144 600 244 300 Plant issue fee					
Multiple Dependent	122 130 122 130 Petitions to the Commissioner					
	123 50 123 50 Processing fee under 37 CFR 1 17(q)					
Large Entity Small Entity Fee Fee Fee Fee Description	126 180 126 180 Submission of Information Disclosure Stmt					
Code (\$) Code (\$)	581 40 581 40 Recording each patent assignment per property (times number of properties)					
103 18 203 9 Claims in excess of 20 102 80 202 40 Independent claims in excess of 3						
102 80 202 40 Independent claims in excess of 3 104 270 204 135 Multiple dependent claim, if not paid	146 710 246 355 Filing a submission after final rejection (37 CFR § 1 129(a))					
109 80 209 40 ** Reissue independent claims over original patent	149 710 249 355 For each additional invention to be examined (37 CFR § 1 129(b))					
110 18 210 9 ** Reissue claims in excess of 20	179 710 279 355 Request for Continued Examination (RCE)					
and over original patent	169 900 169 900 Request for expedited examination of a design application					
SUBTOTAL (2) (\$) O	Other fee (specify)					
**or number previously paid, if greater, For Reissues, see above Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)						

SUBMITTED BY			Complete (if applicable)			
Name (Pnnt/Type)	Mark Chao,	, P\$7.D., JD.	Registration No. (Attorney/Agent)	37,293	Telephone	(847) 383-3372
Signature	2/1/	ho			Date	10/29/21

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

tba

Filed:

tba

1st Inventor:

H. ODAKA.

For:

Pharmaceutical Composition For The Treatment of Diabetes

Atty. Dkt. No.

2530 US1P

Art Unit

tha

Evaminer

tha

Allowed:

Batch:

Paper No.:

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EL 792689035 US

DATE IN:

October 29, 2001

Itemized Papers/Items:

- 1. This certificate and a Return Receipt Postcard (2 pages.)
- 2. Transmittal Form (1 page) + Fee Transmittal (1 page X2)
- 3. Specification 40 total pages, including Claims 1-21 (3 pages.), Abstract (1 page)]
- 4. First Preliminary Amendment (9 pages)
- 5. Executed Declaration/Power of Attorney (3 pages) (copy)
- 6. Information Disclosure Statement (1 page) with Form PTO 1449 (2 pages)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

BOX Patent Application Commissioner for Patents Washington, D.C. 20231.

on this date, October 29, 2001

Dated: 10/29/01

Gail L. Winokur